Sex n (%) | Age (mean ± SD) | BDAI (mean ± SD) | VAS (itching) | Anti-BMZ antibodies | |
---|---|---|---|---|---|
66.3 ± 15.0 | 39 ± 16 | 4 - 10 (median 8) | 1:80 to 1:320 (median 1:160) | ||
36.9 ± 12.5 | - | - | - |
Polymorphism | BP n=71 n (%) | Controls n=100 n (%) | p-value | OR (95% CI) |
---|---|---|---|---|
29 (40.8) | 48 (48) | 0.3541 | 0.75 (0.40-1.38) | |
42 (59.2) | 52 (52) | 0.3541 | 1.34 (0.72-2.47) | |
51 (71.8) | 76 (76) | 0.5389 | 0.81 (0.40-1.61) | |
20 (28.2) | 24 (24) | 0.5389 | 1.24 (0.62-2.48) | |
20 (28.2) | 37 (37) | 0.2274 | 0.67 (0.35-1.29) | |
31 (43.6) | 39 (39) | 0.5412 | 1.21 (0.65-2.25) | |
9 (12.7) | 11 (11) | 0.7368 | 1.17 (0.46-3.00) | |
11 (15.5) | 13 (13) | 0.6437 | 1.23 (0.52-2.92) |
Ile105Val |
BP n=71 n (%) | Controls n=100 n (%) | p-value | OR (95%CI) |
---|---|---|---|---|
Ile/Ile (wild type) | 46 (64.8) | 65 (65) | 0.9772 | 0.99 (0.52-1.87) |
Ile/Val | 20 (28.2) | 31 (31) | 0.6901 | 0.87 (0.45-1.70) |
Val/Val | 5 (7.0) | 4 (4) | 0.5958 | 1.82 (0.47-7.03) |
Ile/Ile (wild type) | 46 (64.8) | 65 (65) | 0.9772 | 0.99 (0.52-1.87) |
Ile/Val and Val/Val | 25 (35.2) | 35 (35) | 0.9772 | 1.01 (0.53-1.91) |
Ile | 112 (78.9) | 161 (80.5) | 0.7118 | 0.90 (0.53-1.54) |
Val | 30 (21.1) | 39 (19.5) | 0.7118 | 1.11 (0.65-1.89) |
GSTs polymorphisms | BP n=71 n (%) | Control n=100 n (%) | p-value | OR (95% CI) | ||
---|---|---|---|---|---|---|
Ile/Ile | 14 (19.7) | 23 (23.0) | 0.6076 | 0.82 (0.39- 1.74) | ||
Ile/Ile | 6 (8.5) | 10 (10.0) | 0.7318 | 0.83 (0.29- 2.40) | ||
Ile/Ile | 21 (29.6) | 23 (23.0) | 0.3323 | 1.41 (0.70- 2.80) | ||
Ile/Ile | 5 (7.0) | 9 (9.0) | 0.8594 | 0.77 (0.25- 2.39) | ||
Ile/Val, Val/Val | 3 (4.2) | 1 (1.0) | 0.3889 | 4.37 (0.44-42.88) | ||
Ile/Val, Val/Val | 11 (15.5) | 16 (16.0) | 0.9286 | 0.96 (0.42- 2,22) | ||
Ile/Val, Val/Val | 6 (8.5) | 4 (4.0) | 0.3727 | 2.22 (0.60- 8.16) | ||
Ile/Val, Val/Val | 5 (7.0) | 14 (14.0) | 0.2381 | 0.47 (0.16- 1.36) |